Cell Signaling Technology Logo
1% for the planet logo

SignalSilence® LRF/Pokemon siRNA I #13350

Inquiry Info. # 13350

Please see our recommended alternatives.

    Supporting Data

    REACTIVITY H
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    CST recommends transfection with 100 nM SignalSilence® LRF/Pokemon siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

    Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.

    Storage

    SignalSilence® siRNA is supplied in RNAse-free water. Aliquot and store at -20ºC.

    Product Description

    SignalSilence® LRF/Pokemon siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit LRF (pokemon) expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.

    Quality Control

    Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.

    Background

    Zinc finger and BTB domain-containing protein 7A (LRF, Pokemon, FBI1) is a transcriptional repressor encoded by the ZBTB7A gene that belongs to the POK (POZ and Kruppel)/ZBTB (zinc finger and BTB) family (1). LRF is broadly expressed with elevated expression in a variety of cancers relative to normal tissues, including non-small cell lung cancer, breast cancer, ovarian cancer, prostate cancer, and hepatocellular carcinoma (1-8). Research studies suggest that LRF acts as an oncogene through various mechanisms including repression of the tumor suppressors ARF and Rb, and repression of the cell cycle arrest factor p21Cip1 (9-11). The LRF transcription factor plays key roles during several stages of hematopoiesis including promoting lymphoid progenitor cells to commit to B cell differentiation by repressing T cell-promoting Notch signals, and promoting cell survival during terminal erythroid differentiation through suppression of the proapoptotic factor Bim (12,13).
    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    CST is a registered trademark of Cell Signaling Technology, Inc.
    SignalSilence is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.